利奈唑胺对老年医院获得性肺炎患者治疗的评价

Linezolid in treatment of hospital-acquired pneumonia in senile patients

目的观察利奈唑胺治疗老年医院获得性肺炎(HAP)患者的临床疗效及安全性。方法通过回顾性分析,了解利奈唑胺治疗老年HAP患者痰、血培养证实及高度怀疑革兰阳性球菌感染的疗效和不良反应。结果 76例共89例次应用利奈唑胺治疗的患者,分为细菌培养阳性组42例次及细菌培养阴性组47例次,两组痊愈率分别为40.5%、40.4%,临床缓解率分别为83.3%、83.0%,两组对比,差异无统计学意义;不良反应发生率为33.7%。结论利奈唑胺治疗老年革兰阳性菌感染的HAP患者,安全有效,对于高度怀疑革兰阳性球菌感染的老年HAP患者可经验性使用。

OBJECTIVE To evaluate the efficacy and safety of linezolid in the treatment of hospital-acquired pneumonia（HAP） in senile patients.METHODS A retrospective study was conducted to analyze the clinical efficacy as well as the adverse reactions of linezolid in treatment of gram-positive cocci infections that were highly suspected and confirmed by the culture of sputum and blood.RESULTS Among 76 patients enrolled,there were 89 case-times who received linezolid,which were divided into the positive bacterial culture group（42 case-times） and the negative bacterial culture group（47 case-times）.The cure rates of the two groups were 40.5% and 40.4%,respectively,and the effective rates were 83.3% and 83.0%,respectively,as compared with the two groups,the differences were not statistically significant;the incidence of the adverse reaction was 33.7%.CONCLUSION Linezolid is safe and effective in the treatment of gram-positive cocci infections in HAP patients,it can be used as empirical treatment of highly suspected gram-positive cocci infections in HAP patients.